CJC-1295 Questions Answered From Studies
There are twenty-six questions here. The answers come from early phase-1 safety studies, animal work, FDA papers, and sports rules.
What did CJC-1295 change in people?
CJC-1295 sends the growth gland a release message. Growth hormone rises, along with IGF-1, a liver-made hormone your doctor can test [1].
In phase-1 trials, growth hormone rose 2- to 10-fold [1]. It stayed up at least six days; IGF-1 rose 1.5- to 3-fold for 9 to 11 days.
What is CJC-1295 made from?
CJC-1295 is a man-made chain with thirty protein parts. It copies part of the body's hormone message that starts the gland [5].
The changed parts sit at places 2, 8, 15, and 27. DAC adds a blood-protein link; that stretches the time from 30 minutes to 7 to 8 days [1][5].
How do CJC-1295 with DAC and without DAC differ?
DAC adds a link that joins albumin. This blood protein carries the compound.
Half of CJC-1295 with DAC remains after ~7-8 days [1][5]. The shorter form keeps the same four changed parts.
Its timing is quite different: half remains for about 30 minutes. That's the main timing gap.
How does CJC-1295 make growth hormone rise?
CJC-1295 reaches a receptor, a docking place on the growth gland [1]. That contact releases the hormone stored there.
DAC keeps the compound in blood for days. Insulin-like growth factor 1 and growth hormone then stay raised longer [1][5].
How long is the CJC-1295 half-life?
Half of CJC-1295 with DAC remained after 5.8 to 8.1 days. That result came from healthy adults in phase-1 studies [1].
For the shorter form, half remained about 30 minutes. DAC joins albumin, a blood protein, and makes the time far longer [5].
When might someone notice CJC-1295?
Phase-1 trials found higher growth hormone within hours. The rise followed one CJC-1295 with DAC shot under the skin [1].
IGF-1, a liver-made hormone, stayed raised for one to two weeks. The phase-1 studies didn't ask when people felt a change.
That was a blood result, not a report of more energy. The papers can't give you a sound answer.
Which side effects can CJC-1295 cause?
Phase-1 papers report short-lived skin reactions at the shot [1][16]. They also report facial flushing, headache, and mild nausea.
Those were the more common early effects. FDA also noted heart and blood-vessel warning signs [13].
It raised concern about immune reactions to DAC. The papers can't tell you about long-term safety.
How much is known about CJC-1295 safety?
Phase-1 studies found no serious event at one dose up to 250 micrograms based on each kilogram the person weighed [1]. But the studies were short.
Your later risk remains unanswered. The compound isn't FDA-approved for any use [13].
A phase-2 trial stopped after a fatal heart event. The trial doctor judged the event unrelated to the drug [14].
Does FDA approve CJC-1295?
No. CJC-1295 isn't FDA-approved for any use [13].
In September 2023, FDA put it in Category 2 on a temporary pharmacy list called 503A. The list covers drugs a pharmacy may ask to make specially for one person.
The FDA page current as of April 22, 2026 lists the CJC-1295 nomination as withdrawn and still carries the safety concerns. That wasn't FDA approval or a safety clearance [13].
Is CJC-1295 a steroid drug?
No; CJC-1295 is a chain with thirty protein parts [5]. It doesn't have the chemical base found in a steroid.
The drug uses a receptor, a docking place on the growth gland, to release growth hormone [1]. Male and female sex hormones use different receptors.
The drug types work differently. Calling this compound a steroid would be wrong.
Does CJC-1295 raise testosterone?
CJC-1295 first affects growth hormone and insulin-like growth factor 1 [1]. Those aren't the hormones that first control testosterone.
Published CJC-1295 studies don't prove a testosterone rise. Reports outside trials haven't proved one, and the human trials didn't test the claim well.
What CJC-1295 dosage did published studies use?
Phase-1 trials gave healthy adults one CJC-1295 with DAC shot. Amounts were 30, 60, 125, or 250 micrograms based on each kilogram the person weighed [1].
A later part used 60 micrograms per kilogram for 49 days [16]. Shots came at weekly or every-other-week gaps.
These numbers describe a study, not a dose plan for you. No FDA-approved plan exists [13].
What happens after you stop CJC-1295?
CJC-1295 makes the body release its own growth hormone. After use stops, growth hormone and IGF-1 move back toward their starting points.
That second hormone is made by the liver and measured in blood. With DAC, half leaves every seven to eight days.
Repeating that drop explains why one dose may take about four to five weeks to fall below a test's reach [1]. That's what the time figure means for testing.
Did CJC-1295 studies find hair loss?
Hair loss wasn't reported in the phase-1 CJC-1295 trials [1][16]. Yet those studies didn't measure hair changes.
Silence in a paper isn't proof of safety. Some users have reported hair loss online.
Those reports come from users; a controlled trial hasn't tested the claim. The papers can't tell you there is a cause or safety.
Can CJC-1295 cause facial flushing?
Yes. Phase-1 CJC-1295 trials reported brief facial flushing [1].
It was one of the more common early effects. Growth-hormone release can briefly widen blood vessels.
That may make your face warm or red. The flushing stopped on its own in the tested group.
How are CJC-1295 and ipamorelin different?
CJC-1295 copies the hormone message that starts the growth gland [1]. Ipamorelin docks at a different receptor, or receiving place on a gland cell [7].
Ipamorelin has five protein parts. Both compounds can release growth hormone in different ways.
Studies found a larger hormone burst when both were present [8]. Your health may not change at all; the study can't say.
Did CJC-1295 studies find weight gain?
The papers measured blood changes, body tissue apart from fat, fat, and water-retention signs [3][4]. They didn't use scale weight as the main human result.
Short-term water retention has been described for this drug group. Long-term body changes from CJC-1295 remain unclear; the papers leave your scale-weight question open.
What do CJC-1295 studies say about fertility?
No human fertility trial exists for CJC-1295. Public papers also lack animal work on birth safety.
CJC-1295 first affects insulin-like growth factor 1 and growth hormone. It doesn't first affect hormones tied to sex and fertility.
An indirect effect is only a guess. Take that gap to your doctor.
Why do researchers study CJC-1295?
Researchers study CJC-1295 because it keeps growth hormone and IGF-1 raised [1]. Human papers tracked those blood tests and their natural bursts.
In 2006, Alba studied mice that lacked the growth-gland message [3]. The mice regained weight, body tissue apart from fat, and fat under the skin; other papers let you check the timing in healthy adults [1][2].
How long does CJC-1295 remain in your blood?
Half of CJC-1295 with DAC remains after 7 to 8 days [1]. A lab may find it in your blood for about four to five weeks after one dose.
Without DAC, Modified GRF (1-29), or CJC-1295, clears within hours. Labs approved by WADA, the world sports-ban agency, use special tests [12]; athletes face separate banned-drug rules.
Are CJC-1295 and sermorelin the same?
No. Both copy the same body message (1-29), but they aren't built alike.
Sermorelin is the unchanged parent, with half left after 7 to 20 minutes [10]. CJC-1295 has four changed parts.
Its DAC form also binds a blood protein. That difference helps you read the ~7-8 day result [1][5].
Why do researchers pair CJC-1295 with ipamorelin?
CJC-1295 and ipamorelin use different receptors on the same kind of gland cell [7]. A receptor is a place where a drug docks.
Using both compounds produced a larger growth-hormone burst [8]. In some animal tests, the combined rise topped the two separate rises added together.
That animal finding doesn't prove better health for you. The human question remains open.
Did CJC-1295 trials study sleep?
A 1992 study gave the body's natural message through the nose [9]. Deep sleep rose, while early-night cortisol fell.
That study wasn't about CJC-1295. CJC-1295 phase-1 trials didn't use an overnight sleep test; so the direct effect on your sleep is still unknown.
Where did CJC-1295 researchers give the shot?
Phase-1 trials gave CJC-1295 with DAC under the skin [17]. Researchers used belly or thigh tissue.
This is the human route with published records of how long it stayed in blood. No human CJC-1295 trial compared a shot into muscle or a vein [17]; a study route isn't a how-to guide for you.
How often did CJC-1295 studies give a shot?
With DAC, half remained after ~7-8 days. One phase-1 study part used 60 micrograms per kilogram for 49 days [16].
Shots came weekly or every other week. The shorter form has a ~30-minute half-life.
Papers tested the shorter form more often. Those study gaps aren't a dose plan for you.
How does modified GRF (1-29) differ?
Modified GRF is the shorter CJC-1295 form. It has the same thirty protein parts and four changes, but no DAC [5].
It is CJC-1295 without the albumin link. Those four changes make breakdown slower [6]; the 30 minute mark tells you when half is left.